693 matches
-
Sureda A, Robinson S, Canals C et al. Reduced-intensity condiționing compared with convențional allogeneic stem-cell transplantation în relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-462. 7. Sureda A. Autologous and allogeneic stem cell transplantation în Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 943-960. 8. David KA, Mauro L, Evens AM. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 455-462. 7. Sureda A. Autologous and allogeneic stem cell transplantation în Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 943-960. 8. David KA, Mauro L, Evens AM. Relapsed and refractory Hodgkin lymphoma: transplantation strategies and novel therapeutic options. Curr Treat Options Oncol 2007; 8: 352-374. 9. Schulz H, Rehwald U, Morschhauser F et al. Rituximab
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2. Shipp M, Harrington D, Anderson J et al. A predictive model for aggressive nonHodgkin's lymphoma. N Engl J Med 1993; 329: 987-994. 3. Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 1-8. 4. Reyes F, Lepage E, Ganem G et al. ACVBP versus CHOP plus radiotherapy în localized aggresive lymphoma. N Engl J Med 2005; 352: 1197-1205. 5. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Med 2002; 346: 235-242. 6. Bonnet C, Fillet G, Mounier N et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma în elderly patients: a study of the Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 1-6. 7. Pfreundschuh M, Trumper L, Kloess M et al. German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
or primary refractory diffuse large B cell lymphoma. Blood 2004; 103: 3684-3688. 12. Khouri IF, Saliba RM, Hosing C et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240-2247. 13. Horwitz SM, Negrin RS, Blume KG et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive nonHodgkin lymphoma. Blood 2004; 103: 777-783. Limfomul gastric de zona marginală tip MALT Recomandări
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
and treatment: what has changed over the past 10 years? Br J Haematol 2007; 136: 521-538. 2. Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007; 63:245-256. 3. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005; 23: 6415-6420. 4. Levy M, Copie-Bergman C, Traulle C et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 2002; 97: 292-297. 5. Koch P
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
of response and outcome. Am J Gastroenterol 2002; 97: 292-297. 5. Koch P, Probst A, Berdel WE et al. Treatment results în localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23: 7050-7059. 6. Martinelli G, Laszlo D, Ferreri AJ et al. Clinical activity of rituximab în gastric marginal zone nonHodgkin's lymphoma resistant to or not eligibile for Anti helicobacter pylori Therapy. J Clin Oncol 2005; 23: 1979-1983
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
NHL 02/96). J Clin Oncol 2005; 23: 7050-7059. 6. Martinelli G, Laszlo D, Ferreri AJ et al. Clinical activity of rituximab în gastric marginal zone nonHodgkin's lymphoma resistant to or not eligibile for Anti helicobacter pylori Therapy. J Clin Oncol 2005; 23: 1979-1983. 7. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of helicobacter pylori can be managed safely by a watch and wait strategy: experience
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
of survival în follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 351:21592169.[Abstract/Free Full Text] 4. Cheson B, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 25:579-586.[Abstract/Free Full Text] 5. MacManus PM, Hoppe RT. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University. J Clin
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Clin Oncol (2007) 25:579-586.[Abstract/Free Full Text] 5. MacManus PM, Hoppe RT. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University. J Clin Oncol (1996) 14:1282-1290.[Abstract/Free Full Text] 6. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2005) 105:14171423.[Abstract/Free Full Text] 7
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
x4 schedule. Blood (2004) 103:4416-4423.[Abstract/Free Full Text] 9. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival în relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol (2003) 21:3918-3927.[Abstract/Free Full Text] 10. Morschhauser F, Radford J, Van Hoof A, et al. Phase III randomized study of consolidation therapy with 90Y-Ibritumomab Tiuxetan after first remission în advanced follicular lymphoma. J Clin Oncol (2008) 26
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
CUP trial. J Clin Oncol (2003) 21:3918-3927.[Abstract/Free Full Text] 10. Morschhauser F, Radford J, Van Hoof A, et al. Phase III randomized study of consolidation therapy with 90Y-Ibritumomab Tiuxetan after first remission în advanced follicular lymphoma. J Clin Oncol (2008) 26:5156-5164.[Abstract/Free Full Text] 11. Dreyling M, Trumper L, von Schilling C, et al. Results of a național consensus workshop: therapeutic algorithm în patients with follicular lymphoma-role of radioimmunotherapy. Ann Hematol (2007) 86:81-87.[CrossRef][ISI
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Med 2003; 349: 2091-2098. 6. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate în advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group Study. J Clin Oncol 1992; 10: 1245-1251. 7. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. 8. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Engl J Med 2006; 354: 567-578. 8. Hitt R, Lopez-Pousa A, Martinez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy în locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645. 9. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel în head and neck cancer. N Engl J Med 2007; 357: 1705-1715. 10. Vermorken JB, Remener E, van Herpen C
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 16141619. 5. Leung SF, Zee B, Ma BB et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements TNM staging în nasopharyngeal carcinoma prognostication. J Clin Oncol 2006; 34: 5414-5418. 6. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy în patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317. 7. Chan AT, Leung SF, Ngan
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
acid quantitation complements TNM staging în nasopharyngeal carcinoma prognostication. J Clin Oncol 2006; 34: 5414-5418. 6. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy în patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 1310-1317. 7. Chan AT, Leung SF, Ngan RK et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone în locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97: 536-539. 8. Lin JC, Jan JS, Hsu
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2005; 97: 536-539. 8. Lin JC, Jan JS, Hsu CY et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637. 9. Kwong DL, Sham JS, Au GK et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004; 22: 2643-2653. 10. Wee J, Tan EH, Tai BC et al. Randomized trial
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003; 21: 631-637. 9. Kwong DL, Sham JS, Au GK et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004; 22: 2643-2653. 10. Wee J, Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy în patients with American Joint Committee on Cancer/International Union against cancer stage III and IV
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Tan EH, Tai BC et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy în patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005; 23: 6730-6738. 11. Lee AWM, Lau WH, Tung SY et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Clin Oncol 2005; 23: 6730-6738. 11. Lee AWM, Lau WH, Tung SY et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005; 23: 6966-6975. 12. Baujat B, Audry H, Bourhis J et al. Chemotherapy în locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
patients. Int J Radiat Oncol Biol Phys 2006; 64: 47-56. 13. Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-1124. 14. Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function în early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873-4879. 15. Ma BB, Chan AT. Recent
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-1124. 14. Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensitymodulated radiotherapy on salivary gland function în early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007; 25: 4873-4879. 15. Ma BB, Chan AT. Recent perspectives în the role of chemotherapy în the management of advanced nasopharyngeal carcinoma. Cancer 2005; 103: 22-31. Gliomul malign Recomandările ESMO pentru diagnosticare, tratament și monitorizare R. Stupp*1) amp
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
endocrinologie care au dotarea și expertiza necesară se recomandă că înainte de a incepe tratamentul cu Lanreotidum să se efectueze un test de supresie cu octreotidum (măsurarea hormonului somatotrop - GH orar, timp de 6 ore, după octreotid 100 f2æg sc) (vezi Clin Endocrinol - Oxford - 2005, 62, 282-288). Această testare este opțională. IV. CRITERIILE DE EVALUARE A EFICACITĂȚII TERAPEUTICE URMĂRITE ÎN MONITORIZAREA PACIENȚILOR DIN PROGRAMUL TERAPEUTIC CU LANREOTIDUM (SOMATULINE PR) Reevaluările pentru monitorizarea pacienților din programul terapeutic cu lanreotidum vor fi efectuate de
EUR-Lex () [Corola-website/Law/242307_a_243636]
-
șnur textil de culoare portocalie. B. Șepcuța cu cozoroc Se confecționează din material textil de culoare bleumarin pentru efectivele din grupa C, bleumarin indigo pentru celelalte structuri. Pentru poliția rutieră se poate realiza de culoare albă. Calota este confecționată în clini. Pe partea frontală a calotei, pe mijloc, se aplică emblema. Deasupra emblemei poate fi inscripționată denumirea structurii. La spate este prevăzută cu sistem reglabil de fixare. Cozorocul este simplu. Pentru efectivele instituțiilor de învățământ, pe partea frontală a calotei are
EUR-Lex () [Corola-website/Law/224640_a_225969]
-
enormi de mare zero. Vorba cântecului: au făcut dinți copiii noștri. Fandare și fardare mioritică. Bine măcar că la Cotroceni sunt ultimele zile ale portocaliului alcoolist, ce sforăie ca un marinar beat. Cei mai mulți dintre "politicienii" de azi nu au nici în clin, nici în mânecă cu politica. Afilierea la un partid este dictată de interesele conjuncturale, nu de vreo apropiere de o ideologie sau doctrină anume. Liderii partidelor, oricare ar fi fost ele, n-au ținut cu tot dinadinsul să păstreze o
UN PUI DE EDITORIAL. DE CE SUNTEM CERŞETORI ÎN PROPRIA ŢARĂ? de POMPILIU COMSA în ediţia nr. 1432 din 02 decembrie 2014 by http://confluente.ro/pompiliu_comsa_1417513200.html [Corola-blog/BlogPost/371931_a_373260]